| |
 |
      
|
DNA Vaccine Design for HIV-1 Infection
| |
HIV Clade B: North
America and Western Europe (PENNVAX™-B) |
| |
HIV Clades A, C, and D: Developing
regions of Africa and Asia (PENNVAX™-G) |
| |
VGX Strategy for World AIDS Vaccine |
|
|
Develop Synthetic Consensus (SynCon™)
DNA Vaccine Constructs for HIV Envelope Clades A, B, C, and
D |
|
|
Develop SynCon™ DNA Vaccine
Constructs for Gag and Pol Proteins |
 |
VGX HIV Vaccine Trial Strategies
Conduct Clinical Testing with
Clinical Partners
| |
Prophylactic Clade
B Vaccine: Collaborations w/ HIV Vaccine Trials (PENNVAX™-B)
Network (HVTN) |
|
|
|
- PENNVAX™-B + Cytokine (IL-12 and IL-15)
Genes (HVTN-070 Study) – Phase I initiated |
|
|
- PENNVAX™-B + CELLECTRA® EP (Planned
with HVTN) |
| |
Prophylactic Clades A, C, and D Vaccines: (PENNVAX™-G) |
|
|
- PENNVAX™-G + CELLECTRA® EP |
| |
Therapeutic Clade B Vaccine: |
|
|
- PENNVAX™-B + CELLECTRA® EP |
SynCon™ DNA Vaccines for HIV: Increased
T Cell Immune Responses in Monkey Models
|
|
HIV or SIV vaccines administered
at 1 mg/construct + CELLECTRA® EP |
|
|
10-30x improvement in immunogenicity via other
vaccine methods* |
|
|
“Best” Cytotoxic T Lymphocyte
(CTL) responses in Monkey Models for HIV |
|
|
*Hirao
LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner
DB. Vaccine. 2008 Jan 17;26(3):440-8. Epub 2007 Nov 8. Intradermal/subcutaneous
immunization by electroporation improves plasmid vaccine delivery
and potency in pigs and rhesus macaques.
Cristillo AD, Weiss D, Hudacik L, Restrepo S, Galmin L, Suschak
J, Draghia-Akli R, Markham P, Pal R. Biochem Biophys Res Commun.
2008 Feb 1;366(1):29-35. Epub 2007 Nov 26. Persistent antibody
and T cell responses induced by HIV-1 DNA vaccine delivered
by electroporation. |
|
|
|
